Document Detail


Nitric oxide induced cervical ripening in the human: Involvement of cyclic guanosine monophosphate, prostaglandin F(2 alpha), and prostaglandin E(2).
MedLine Citation:
PMID:  11967501     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of the study was to investigate possible mechanisms and morphologic changes involved in nitric oxide-induced cervical ripening. STUDY DESIGN: Women scheduled for surgical termination of first trimester pregnancy were randomized to 1 of 3 groups: isosorbide 5-mononitrate 40 mg 4 hours or 10 hours before the operation or no preoperative treatment. Cervical specimens were obtained for the analysis of tissue levels of cyclic guanosine monophosphate, cyclic adenosine monophosphate, cyclo-oxygenase 1, cyclo-oxygenase 2, prostaglandin F(2 alpha), and prostaglandin E(2) or were fixed in glutaraldehyde for microscopy. RESULTS: Increased levels of cyclic guanosine monophosphate, cyclo-oxygenase 2, prostaglandin F(2 alpha), and prostaglandin E(2) were found in samples that were exposed to isosorbide 5-mononitrate compared with control samples. Electron microscopy revealed stromal edema and collagen disorganization after isosorbide 5-mononitrate treatment. CONCLUSION: Cyclic guanosine monophosphate, prostaglandin F(2 alpha), and prostaglandin E(2) are involved in nitric oxide-induced cervical ripening. Nitric oxide causes morphologic changes similar to those changes seen during spontaneous cervical ripening.
Authors:
E Ekerhovd; B Weijdegård; M Brännström; I Mattsby-Baltzer; A Norström
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  186     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2002 Apr 
Date Detail:
Created Date:  2002-04-22     Completed Date:  2002-06-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  745-50     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, Göteborg University, Sweden. erling.ekerhovd@obgyn.gu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cervical Ripening*
Cervix Uteri / anatomy & histology,  chemistry,  drug effects
Cyclic AMP / analysis
Cyclic GMP / analysis,  physiology*
Cyclooxygenase 1
Cyclooxygenase 2
Dinoprost / analysis,  physiology*
Dinoprostone / analysis,  physiology*
Female
Gestational Age
Humans
Immunoblotting
Isoenzymes / analysis
Isosorbide Dinitrate / administration & dosage,  analogs & derivatives,  pharmacology
Membrane Proteins
Microscopy, Electron
Nitric Oxide / physiology*
Nitric Oxide Donors / administration & dosage,  pharmacology
Pregnancy
Prostaglandin-Endoperoxide Synthases / analysis
Chemical
Reg. No./Substance:
0/Isoenzymes; 0/Membrane Proteins; 0/Nitric Oxide Donors; 10102-43-9/Nitric Oxide; 16051-77-7/isosorbide-5-mononitrate; 363-24-6/Dinoprostone; 551-11-1/Dinoprost; 60-92-4/Cyclic AMP; 7665-99-8/Cyclic GMP; 87-33-2/Isosorbide Dinitrate; EC 1.14.99.1/Cyclooxygenase 1; EC 1.14.99.1/Cyclooxygenase 2; EC 1.14.99.1/PTGS1 protein, human; EC 1.14.99.1/PTGS2 protein, human; EC 1.14.99.1/Prostaglandin-Endoperoxide Synthases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Factors that predict low hematocrit levels in the postpartum patient after vaginal delivery.
Next Document:  Clinical predictors for a high risk for the development of diabetes mellitus in the early puerperium...